Connect with us

Press Releases

Nordic Group B.V. Appoints Ophthalmology Innovator, Eric D. Donnenfeld, MD as Medical Advisory Board Chair




(PRESS RELEASE) BERWYN, PA – Amring Pharmaceuticals Inc. (Amring), a subsidiary of Nordic Group B.V. (Nordic Pharma), announced today that preeminent ophthalmologist Eric D. Donnenfeld, MD will Chair its U.S. Medical Advisory Board (MAB) which includes Richard Lindstrom, MD (Minnesota), Vance Thompson, MD (South Dakota), Preeya Gupta, MD (North Carolina), Paul Karpecki, OD (Kentucky), Lisa Nijm, MD, JD (Illinois), and Selina McGee, OD (Oklahoma).

Dr. Donnenfeld joins the MAB as Nordic Pharma prepares to launch a novel therapy for Dry Eye Disease, LACRIFILL® canalicular gel. The FDA-cleared hyaluronic acid derivative LACRIFILL is intended to temporarily block tear drainage by the occlusion of the canalicular system.

“Nordic Pharma continues to build a world class group of key opinion leaders with Eric agreeing to lead our esteemed MAB in the U.S. as we prepare to bring LACRIFILL to market. With over 30 years of clinical experience as an internationally recognized expert and pioneer in refractive, cornea and cataract surgery he brings invaluable insights for developing physician led strategies, enhancing the patient experience and phase IV study initiatives.” said Philip Gioia, President of the U.S. team that will launch LACRIFILL under the Nordic
Pharma brand. “As one of the leading refractive and cataract surgeons in the United States he shares Nordic Pharma’s commitment to making a sustainable impact on the health of people with dry eye disease.”

“I have been fortunate to work closely with Eric over the last 20 years. He is an outstanding clinician and surgeon with a pulse on new technology,” said Jai G. Parekh, MD, MBA, Chief Commercial Officer of Nordic Pharma Eye Care U.S. “Eric is responsible for many of the most successful launches in eye care and our team looks forward to collaborating with him. He will be instrumental in guiding us during LACRIFILL’s introduction to eye care providers and patients.”

“I’m excited to be part of the LACRIFILL launch as this technology is disruptive and will change the way we practice ophthalmology and optometry.” said Dr. Donnenfeld. “It’s an honor to be working with Nordic Pharma’s leadership and our highly respected Medical Advisory Board to bring this novel dry eye disease therapy to ophthalmologists and optometrists across the U.S. and then around the world.”

In addition to Dr. Donnenfeld’s appointment, Nordic Pharma has proudly accepted an invitation to join the American-European Congress of Ophthalmic Surgery (AECOS) and will have a significant presence at the AECOS Winter Symposium this week. Dr. Vance Thompson will be sharing benefits of LACRIFILL with physicians and leaders in ophthalmology. Select pre-order opportunities will also be discussed. Dr. Thompson will also be presenting the Dry Eye Disease Update session.




The Best Overall Progressive Lens, Now Powered by AI

Engineered with Behavioral Artificial Intelligence and utilizing new XR-motion™ technology, Varilux XR series goes beyond prescription and eye physiology to consider the patient’s visual behavior and design a progressive lens that respects how
their eyes naturally move.

Varilux XR series comes in two versions, Varilux® XR design and Varilux® XR track. The Varilux XR track lens provides an additional level of personalization by incorporating the exclusive Near Vision Behavior Measurement, providing up to 25% more near vision width3 according to the patient’s need, so patients get the highest level of customization.

Discover Varilux XR series and enjoy instantly sharp vision in motion4 and seamless transitions from near to far.

For more information, visit here.

Promoted Headlines






Get the most important news and business ideas for eyecare professionals every weekday from INVISION.


Most Popular